| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/30/2003 | US20030022813 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022812 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 01/30/2003 | US20030022338 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 01/30/2003 | US20030022272 Method of inducing an antigen-specific anticytotoxic cell |
| 01/30/2003 | US20030022238 Methods of identifying agents which inhibit GPR-9-6 |
| 01/30/2003 | US20030022211 Nucleotide sequences coding polypeptide for use in diagnosis and prevention of psychological and nervous system disorders |
| 01/30/2003 | US20030022185 Secreted protein HLHFP03 |
| 01/30/2003 | US20030021808 Cd40 ligand adjuvant for respiratory syncytial virus |
| 01/30/2003 | US20030021798 Use of mCRP to enhance immune responses |
| 01/30/2003 | US20030021792 Quantitative analysis; immunosuppressants, anticoagulants |
| 01/30/2003 | US20030021769 Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer |
| 01/30/2003 | US20030021766 Nucleic acid mucosal immunization |
| 01/30/2003 | US20030021765 Polymer conjugates of interferon beta-1a and uses |
| 01/30/2003 | US20030021755 Headache therapy |
| 01/30/2003 | US20030021754 Aerosols; vaporization, cooling |
| 01/30/2003 | US20030021753 Delivery of antiemetics through an inhalation route |
| 01/30/2003 | CA2730856A1 Capsular polysaccharide solubilisation and combination vaccines |
| 01/30/2003 | CA2454307A1 Human type antihuman ige receptor antibody and antibody fragment |
| 01/30/2003 | CA2454185A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | CA2454059A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | CA2453967A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453965A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | CA2453765A1 Polysaccharidic esters of retinoic acid |
| 01/30/2003 | CA2453636A1 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 01/30/2003 | CA2453602A1 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 01/30/2003 | CA2453294A1 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | CA2452678A1 Combination of eplerenone and an hmg coa reductase inhibitor |
| 01/30/2003 | CA2452322A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | CA2452009A1 Chemical compounds |
| 01/30/2003 | CA2451530A1 Chemical compounds |
| 01/30/2003 | CA2451392A1 Prostaglandin analogues as ep4 receptor agonists |
| 01/30/2003 | CA2450437A1 1-phenylsulphonyl-1,3-dihydro-2h-indol-2-one derivatives, their preparation and their therapeutic application |
| 01/29/2003 | EP1279729A1 Factors participating in degranulation of mast cells, dnas encoding the same, method of screening inhibitors of these factors and the inhibitors |
| 01/29/2003 | EP1279728A1 Generation of fully mature and stable dentritic cells from leukapheresis products for clinical applications |
| 01/29/2003 | EP1279674A2 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
| 01/29/2003 | EP1279666A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/29/2003 | EP1279662A1 Process for preparing phenylcyclohexan-1-ylcarboxylic acids |
| 01/29/2003 | EP1279406A1 Transporters and drug delivery system by using the same |
| 01/29/2003 | EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases |
| 01/29/2003 | EP1278881A1 Hybrid glycosylated products and their production and use |
| 01/29/2003 | EP1278870A1 Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| 01/29/2003 | EP1278869A2 Proteases |
| 01/29/2003 | EP1278859A2 Human protein kinases and protein kinase-like enzymes |
| 01/29/2003 | EP1278846A2 Cytoskeleton-associated proteins |
| 01/29/2003 | EP1278843A2 Rna metabolism proteins |
| 01/29/2003 | EP1278826A1 Novel proteins |
| 01/29/2003 | EP1278825A2 Methods of producing membrane vesicles |
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278765A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 01/29/2003 | EP1278763A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
| 01/29/2003 | EP1278761A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 01/29/2003 | EP1278751A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| 01/29/2003 | EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278723A2 P-(sulfonyl)-aryl and -heteroaryl amines |
| 01/29/2003 | EP1278722A1 Aryl and heteroaryl sulfonates |
| 01/29/2003 | EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1278542A2 Molecular antigen arrays and vaccines |
| 01/29/2003 | EP1278535A2 Uses of tgap7 for the modulation of leucocyte activation |
| 01/29/2003 | EP1278532A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278530A2 Chemical modification of mammalian urine and blood |
| 01/29/2003 | EP1278528A1 Nucleoside analogs with carboxamidine-modified bicyclic base |
| 01/29/2003 | EP1278509A1 Lipochroman-6 as no-synthase inhibitor and uses |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1278429A1 Process for enhancing immune response in canines using a dietary composition including garlic |
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1102761B1 Cyclopentabenzofuran derivatives and their use |
| 01/29/2003 | EP1033369B1 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP1028948B1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 01/29/2003 | EP0832081B1 Bicyclic-aromatic compounds |
| 01/29/2003 | EP0753005B1 Cytotoxic t-cell lymphocyte ("ctl") activity regulation by class i mhc peptides |
| 01/29/2003 | CN1394206A Novel vitamin D analogues |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1393250A Aqueous extract of sapanwood for treating acute rejection reaction after organ transplantation |
| 01/29/2003 | CN1099894C Vaccine composition for eliciting immune response against N-glycolylated gangliosides and its use |
| 01/29/2003 | CN1099875C Dermatosis treating medicine |
| 01/28/2003 | WO2002018372A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 01/28/2003 | US6512104 Interleukin-1β converting enzyme like cysteine protease |
| 01/28/2003 | US6512101 Branched hydrazone linkers |
| 01/28/2003 | US6512007 Treatment of inflammatory processes induced by excessive expression of the IL-6-induced acute phase proteins |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511965 Ether type lipid A 1-carboxylic acid analogs |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511685 Heating in presence of bacteria then yeast; adding calcium, magnesium and/or potassium components; filtering and drying |
| 01/28/2003 | US6511683 Enchinacea supplement and method of manufacture |
| 01/28/2003 | US6511666 Purified antigenic complex comproised of multimeric protein complexes of arginine- and lysine-specific thiol endopepti-dases containing adhesion domains; raising antibody response against porphyromonas gingivalis |
| 01/28/2003 | US6511661 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/27/2003 | WO2002009745A1 Medicament for the immunotherapy of malignant tumours |
| 01/27/2003 | CA2417374A1 Medicament for the immunotherapy of malignant tumours |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006636A1 Reduction of the stimulatory capacity of antigen-presenting cells |